Oxfam report "Investing for Life": Company responses

The Business & Human Rights Resource Centre invited all 12 [pharmaceutical] companies to respond to the report. The results to date are below (any future responses received will be added to this page)...On 6 February 2008 Oxfam sent a rejoinder, commenting on the company responses... - Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi-Aventis responded - Roche, Eli Lilly declined to respond - Bristol-Myers Squibb, Wyeth did not respond

Línea del tiempo

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Feb 2008

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

19 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

18 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

18 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Fecha:

12 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Oxfam report "Investing for Life": Company responses

Fecha:

12 Dic 2007

Tipo de contenido:

Artículo

Idiomas disponibles: English
La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Fecha:

27 Nov 2007

Tipo de contenido:

Artículo
Oxfam says top drug companies focusing on patents, not poor

Fecha:

26 Nov 2007

Tipo de contenido:

Artículo

Idiomas disponibles: English
L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Fecha:

23 Nov 2007

Tipo de contenido:

Artículo

Idiomas disponibles: français
Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Nov 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices

Fecha:

1 Nov 2007

Tipo de contenido:

Artículo

Idiomas disponibles: English

Ver la historia completa

Cargar más Ver menos

Business & Human Rights
Resource Centre

El Tratado entre México, Estados Unidos y Canadá (T-MEC) y el panorama laboral en la industria de la indumentaria

Comunidad sobre Debida Diligencia en Derechos Humanos en la Agroindustria

Actualización Semanal 19 de diciembre de 2024

Actualizaciones Trimestrales de Responsabilidad Legal Empresarial – Número 51, diciembre de 2024: Negociaciones del tratado vinculante 2024: Panorama general, cuestiones clave y oportunidades

Centro de Información sobre Empresas y Derechos Humanos

El Tratado entre México, Estados Unidos y Canadá (T-MEC) y el panorama laboral en la industria de la indumentaria

Comunidad sobre Debida Diligencia en Derechos Humanos en la Agroindustria

Actualización Semanal 19 de diciembre de 2024

Actualizaciones Trimestrales de Responsabilidad Legal Empresarial – Número 51, diciembre de 2024: Negociaciones del tratado vinculante 2024: Panorama general, cuestiones clave y oportunidades

Esta página no está disponible en Español y está siendo mostrada en English

Oxfam report "Investing for Life": Company responses

Línea del tiempo

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Oxfam report "Investing for Life": Company responses

La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Oxfam says top drug companies focusing on patents, not poor

L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices